Cargando…

Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes

The selection of viral strains with resistance-associated substitutions at hepatitis C virus (HCV) NS5A and NS5B genes is considered one of the limiting factors for achieving sustained virologic response (SVR) to combination of direct-acting antivirals daclatasvir (DCV) and sofosbuvir (SOF). Since 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costa, Vanessa D., Brandão-Mello, Carlos E., Nunes, Estevão P., dos Santos Silva, Pedro Guilherme Corôa, de Souza Rodrigues, Lia Laura Lewis Ximenez, Lampe, Elisabeth, do Amaral Mello, Francisco Campello
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504041/ https://www.ncbi.nlm.nih.gov/pubmed/31063475 http://dx.doi.org/10.1371/journal.pone.0216327

Ejemplares similares

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2013)

Performance of NS3, NS5a AND NS5b Hepatitis C Virus (HCV) Antiviral Resistance Sequencing Assays
por: Nutt, Jamie, et al.
Publicado: (2017)

A41 Characterization of NS5 coding region resistance associated substitutions from DAA-naïve GT1 HCV-infected patients in a Portuguese cohort
por: Brandao, R, et al.
Publicado: (2018)

Induction of Intrahepatic HCV NS4B, NS5A and NS5B-Specific Cellular Immune Responses following Peripheral Immunization
por: Lang Kuhs, Krystle A., et al.
Publicado: (2012)

Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy
por: Leuştean, Anca, et al.
Publicado: (2021)

New insights regarding HCV-NS5A structure/function and indication of genotypic differences
por: Yamasaki, Lilian HT, et al.
Publicado: (2012)

Correction: Induction of Intrahepatic HCV NS4B, NS5A and NS5B-Specific Cellular Immune Responses following Peripheral Immunization
por: Lang Kuhs, Krystle A., et al.
Publicado: (2013)

Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis
por: Santos, Ana Paula de Torres, et al.
Publicado: (2022)

A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2015)

Serological and molecular characterization of hepatitis B virus infection in chronic kidney disease patients from Rio de Janeiro, Brazil
por: Villar, Livia Melo, et al.
Publicado: (2022)

Correction: A Conserved NS3 Surface Patch Orchestrates NS2 Protease Stimulation, NS5A Hyperphosphorylation and HCV Genome Replication
por: Isken, Olaf, et al.
Publicado: (2016)

Exploring NS3/4A, NS5A and NS5B proteins to design conserved subunit multi-epitope vaccine against HCV utilizing immunoinformatics approaches
por: Ikram, Aqsa, et al.
Publicado: (2018)

Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection
por: Sillanpää, Maarit, et al.
Publicado: (2009)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

Perilipin 5 alleviates HCV NS5A-induced lipotoxic injuries in liver
por: Zhang, Jin, et al.
Publicado: (2019)

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283
por: Demetriou, Victoria L, et al.
Publicado: (2010)

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
por: Kwon, Hyock Joo, et al.
Publicado: (2015)

Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors
por: Kaushik-Basu, Neerja, et al.
Publicado: (2008)

Update on different aspects of HCV variability: focus on NS5B polymerase
por: Marascio, Nadia, et al.
Publicado: (2014)

Identification of NS2 determinants stimulating intrinsic HCV NS2 protease activity
por: Isken, Olaf, et al.
Publicado: (2022)

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir
por: Berger, Kristi L., et al.
Publicado: (2016)

First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients
por: Hasanshahi, Zahra, et al.
Publicado: (2021)

Peripheral PD-1(+) T Cells Co-expressing Inhibitory Receptors Predict SVR With Ultra Short Duration DAA Therapy in HCV Infection
por: Romani, Sara, et al.
Publicado: (2019)

Assessing Positivity and Circulating Levels of NS1 in Samples from a 2012 Dengue Outbreak in Rio de Janeiro, Brazil
por: Allonso, Diego, et al.
Publicado: (2014)

Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs
por: Paolucci, Stefania, et al.
Publicado: (2020)

Reflections of NS5 branes
por: Mertens, Adrian
Publicado: (2011)

Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents
por: Bartolini, Barbara, et al.
Publicado: (2017)

Classification of HCV NS5B Polymerase Inhibitors Using Support Vector Machine
por: Wang, Maolin, et al.
Publicado: (2012)

A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome
por: Bagaglio, Sabrina, et al.
Publicado: (2020)

1H-Imidazole-2,5-Dicarboxamides as NS4A Peptidomimetics: Identification of a New Approach to Inhibit HCV-NS3 Protease
por: Omar, Abdelsattar M., et al.
Publicado: (2020)

Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease
por: El-Araby, Moustafa E., et al.
Publicado: (2020)

Increase in Hepatitis A Cases Linked to Imported Strains to Rio de Janeiro, Brazil: A Cross-Sectional Study
por: Mello, Vinicius M., et al.
Publicado: (2022)

Occurrence of genetic modifications in core, 5′UTR and NS5b of HCV associated with viral response to treatment
por: Kanwal, Sobia, et al.
Publicado: (2014)

Discovery of Terpenes as Novel HCV NS5B Polymerase Inhibitors via Molecular Docking
por: Karpiński, Tomasz M., et al.
Publicado: (2023)

Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C
por: Costantino, Angela, et al.
Publicado: (2015)

Risk factors for hepatitis B virus infection in Rio de Janeiro, Brazil
por: Lewis-Ximenez, Lia L, et al.
Publicado: (2002)

No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
por: Hoffmann, Luísa, et al.
Publicado: (2015)

Association of Pre-S/S and Polymerase Mutations with Acute and Chronic Hepatitis B Virus Infections in Patients from Rio de Janeiro, Brazil
por: de Almeida Ribeiro, Camilla Rodrigues, et al.
Publicado: (2022)

Resistance mutations of NS3 and NS5b in treatment-naïve patients infected with hepatitis C virus in Santa Catarina and Rio Grande do Sul states, Brazil
por: Andrade, Elisabete, et al.
Publicado: (2020)

Immunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice
por: Pishraft Sabet, Leila, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r2lhh964stdts1g28olr5nimst